Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy

Kinan Alhallak, Jennifer Sun, Barbara Muz, Amanda Jeske, Julie O’Neal, Julie K. Ritchey, Samuel Achilefu, John F. DiPersio, Abdel Kareem Azab

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Immunotherapy is an attractive approach for treating cancer. T-cell engagers (TCEs) are a type of immunotherapy that are highly efficacious; however, they are challenged by weak T-cell activation and short persistence. Therefore, alternative solutions to induce greater activation and persistence of T cells during TCE immunotherapy is needed. Methods to activate T cells include the use of lectins, such as phytohemagglutinin (PHA). PHA has not been used to activate T cells in vivo, for immunotherapy, due to its biological instability and toxicity. An approach to overcome the limitations of PHA while also preserving its function is needed. In this study, we report a liposomal PHA which increased PHA stability, reduced toxicity and performed as an immunotherapeutic that is able to activate T cells for the use in future cancer immunotherapies to circumvent current obstacles in immunosuppression and T-cell exhaustion.

Original languageEnglish
Pages (from-to)940-944
Number of pages5
JournalJournal of Cellular and Molecular Medicine
Issue number3
StatePublished - Feb 2022


  • T-cell activation
  • immunotherapy
  • nanoparticles


Dive into the research topics of 'Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy'. Together they form a unique fingerprint.

Cite this